Overview
- Imperagen closed a £5 million seed round led by PXN Ventures on Thursday, bringing its total disclosed funding to £8.5 million.
- Guy Levy‑Yurista has been appointed CEO to lead the company’s push to scale R&D, lab automation and commercial partnerships.
- The startup runs a closed‑loop platform that first uses quantum‑physics simulations to generate training data, then trains bespoke AI models and validates top predictions with robotic lab experiments.
- Imperagen told reporters its platform improved two target enzymes by about 677x and 572x in five development cycles with a Fortune 500 personal‑care partner, a company-reported result that still needs independent replication and industrial validation.
- The company plans to target pharmaceuticals, personal care and industrial biotech, but must prove sustained advantage over rivals that use historical data or large protein models before those sectors see broad commercial impact.